Tag: Tiotropium

Posted on

Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with … – PR Newswire (press release)

Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with …
PR Newswire (press release)
Boehringer Ingelheim announced that a comprehensive confirmatory Phase III trial program named UniTinA-asthma™ is ongoing to fully evaluate the potential of the long-acting bronchodilator in the treatment of asthma in pediatric, adolescent and adult …
Promising Phase II Data With Once-Daily Tiotropium may Lead to New Treatment …EIN News (press release)
Results of Phase II Study of Boehringer Ingelheim's Investigational …MarketWatch (press release)

all 4 news articles »

View full post on asthma – Google News

Posted on

Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with … – MarketWatch (press release)

Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with …
MarketWatch (press release)
Boehringer Ingelheim announced that a comprehensive confirmatory Phase III trial program named UniTinA-asthma(TM) is ongoing to fully evaluate the potential of the long-acting bronchodilator in the treatment of asthma in pediatric, adolescent and adult …
Boehringer Ingelheim Announces Positive Phase II Results for Once-Daily …EON: Enhanced Online News (press release)
Results of Phase II Study of Boehringer Ingelheim's Investigational …Sacramento Bee

all 23 news articles »

View full post on asthma – Google News

Posted on

A Randomised, Double- Blind, Placebo Controlled, Cross-over Efficacy and Safety Comparison of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for Four Weeks in Patients With Moderate Persistent Asthma

Condition:   Asthma
Interventions:   Drug: Placebo;   Drug: Tiotropium 5 µg q.d.;   Drug: Tiotropium 2.5 µg b.i.d.
Sponsors:   Boehringer Ingelheim Pharmaceuticals;   Pfizer
Recruiting – verified September 2010

View full post on ClinicalTrials.gov: “Asthma” | updated in the last 30 days

Posted on

Evaluation of Tiotropium 2.5 and 5 Mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 Mcg Twice Daily) in Patient With Moderate Persistent Asthma II

Condition:   Asthma
Interventions:   Drug: 50 mcg salmeterol HFA MDI;   Drug: placebo;   Drug: 5 mcg tiotropium Respimat®;   Drug: 2.5 mcg tiotropium Respimat®
Sponsors:   Boehringer Ingelheim Pharmaceuticals;   Pfizer
Recruiting – verified September 2010

View full post on ClinicalTrials.gov: “Asthma” | updated in the last 30 days

Posted on

Tiotropium Plus Low-Dose Glucocorticoid Effectively Controls Asthma – Medscape


CBC.ca

Tiotropium Plus Low-Dose Glucocorticoid Effectively Controls Asthma
Medscape
Secondary outcome measures included the forced expiratory volume in 1 second (FEV 1 ) before bronchodilation, the number of asthma control days, …
Tiotropium Plus Glucocorticoid Effective in Asthma Patients Combo is superior …ModernMedicine
Possible Alternative Therapy for Adults with Poorly Controlled Asthmanews Stories
An alternate weapon to help adults with asthmaMilwaukee Journal Sentinel (blog)
eMaxHealth –FiercePharma –Sify
all 360 news articles »

View full post on asthma – Google News

Posted on

COPD Drug Spiriva (Tiotropium Bromide) Helps Patients With Poorly Controlled … – Medical News Today


TopNews United Kingdom

COPD Drug Spiriva (Tiotropium Bromide) Helps Patients With Poorly Controlled …
Medical News Today
Spiriva (Tiotropium Bromide) added to low-dose inhaled corticosteroids was found to be effective in the treatment of adults with poorly controlled asthma, …
Study may give alternative to asthma sufferersDenver Post
Pharma co. in asthma flapBoston Herald
Spiriva = Serevent In Asthma StudySpreadit
The Associated Press –ABC7Chicago.com –Healthy Living
all 290 news articles »

View full post on asthma – Google News